Third Rock Ventures’ Love Story With Cancer Immunotherapy Results In The Founding Of Jounce Therapeutics
This article was originally published in The Pink Sheet Daily
The venture firm has pledged $47 million in funding to start-up Jounce Therapeutics to discover and develop biologic drugs for the treatment of cancer.
You may also be interested in...
FDA’s approval of Bristol-Myers Squibb’s metastatic melanoma immunotherapy was granted only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.